IFWM
TEVA icon

Institute for Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Institute for Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-38,940
Closed -$293K – 520
2022
Q2 		$293K Buy
38,940
+9,900
+34% +$86.3K 0.06% 398
2022
Q1 		$273K Buy
+29,040
New +$242K 0.04% 451
2019
Q2 		– Sell
-1,140
Closed -$18K – 494
2019
Q1 		$18K Buy
+1,140
New +$20.1K ﹤0.01% 447

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Institute for Wealth Management's TEVA Position: Q3 2022 in Review

Institute for Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2022, closing a stake of 38,940 shares — an estimated $293K sold.

Institute for Wealth Management first reported a position in TEVA in Q1 2019 and held it in 3 quarters. The position peaked at $293K in Q2 2022. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

  • Institute for Wealth Management reported no remaining Teva Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Institute for Wealth Management sold 38,940 Teva Pharmaceuticals shares in Q3 2022, an estimated $293K.
  • Institute for Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Institute for Wealth Management's Teva Pharmaceuticals position peaked at $293K in Q2 2022.
  • 430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on Institute for Wealth Management's 13F filing for Q3 2022, filed 18 Oct 2022.